Financial events


Financial Times & Deloitte Global Pharmaceutical & Biotechnology Conference

Industry-leading event brings together industry executives, thought leaders and investors wishing to keep abreast of the emerging trends reshaping the global healthcare and life sciences industry.

November 16-17, 2015 | Marriott Grosvenor | London

Explore Content

As the global healthcare industry shifts and transforms, so too must the life science industry. Life science companies will need to adjust strategies to a world in which only true innovation and improved patient outcomes become the key determinant of value in the healthcare system. They will also need to develop commercial models which take account of the changing power balance between provider, payer and patients-all the while keeping a watchful eye on the competitive landscape for the incursion of non-traditional players with whom they will increasingly compete-or partner- to deliver patient-centred products and services. Meanwhile, scrutiny of high prices for speciality drugs and advanced technologies is increasing, impacting the ability of life science companies to bring much needed innovation to patients. How will the industry’s future unfold?

Visit the conference website at to learn more about the speakers, agenda, topics to be covered and to register. Please use marketing code FTDEL to receive 40% off the current registration rate.

Confirmed speakers

  • Dr Severin Schwan, Chief Executive Officer, Roche Group
  • Shaun Grady, Head of Business Operations, AstraZeneca
  • Dr David Meeker, President and Chief Executive Officer, Genzyme
  • Pascale Richetta, Vice President, Western Europe and Canada, AbbVie
  • Jean-Paul Clozel, CEO, Actelion
  • David Redfern, Chief Strategy Officer, GlaxoSmithKline
  • Tuomo Pätsi, President, Europe, Middle East, Africa, Celgene
  • Dr Mohammad Al- Ubaydli, CEO, Patients Know Best
  • Guy Yeoman, Vice President, Patient Centricity, AstraZeneca
  • Alpna Seth, Head of Biosimilar Business Unit, Biogen
  • Dr Stanley Hong, President & CEO, Celltrion Healthcare
  • Professor Dame Sally Davis, Chief Medical and Scientific Officer, Department of Health
  • Jeremy Morgan, International VP Diabetes, Eli Lilly
  • Guido Rasi, Principal Adviser in Charge of Strategy, European Medicines Agency
  • Dr Steve Miller, Chief Medical Officer, Express Scripts
  • Natacha Theytaz, Chief Audit & Risk Advisory Executive, Roche Group
  • Natalie Woodford, Senior Vice President, Talent, Leadership & Organisational Development, GlaxoSmithKline
  • Murray Stewart, Chief Medical Officer, GlaxoSmithKline
  • Susan Herbert, EVP, Global Business Development, Alliance Management, Merck Serono
  • Professor David Haslam, Chair, NICE
  • Dr Ameet Nathwani, Head of Global Medical Affairs, Novartis
  • Eric Cornut, Chief Ethics Compliance and Policy Officer, Novartis
  • Albert Bourla, Group President,Vaccines, Oncology and Consumer Healthcare, Pfizer
  • Jenny Alltoft, Head of Biosimilars, Pfizer
  • Rady Johnson, Executive Vice President, Chief Compliance and Chief Risk Officer, Pfizer
  • Pascale Witz, EVP Global Divisions and Strategic Development, Sanofi
  • Jean-Christophe Tellier, CEO, UCB
  • The Rt Hon George Freeman, MP-Minister of Life Sciences, UK Parliament
  • John Kelland, Director, Manufacturing Relationships, Pharmaceutical Wholesale Division, Walgreens Boots Alliance